EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib

2006 ◽  
Vol 2006 ◽  
pp. 228-229
Author(s):  
N.H. Hanna
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung

60 Afatinib in EGFR mutation positive advanced non-small cell lung cancer

Lung Cancer ◽  
2016 ◽  
Vol 91 ◽  
pp. S22
Author(s):  
R.S. Davies ◽  
A.E. Brewster ◽  
M.R. Button ◽  
J.F. Lester
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation

2020 ◽  
Vol 16 (21) ◽  
pp. 1537-1547
Author(s):  
Fumio Imamura ◽  
Madoka Kimura ◽  
Yukihiro Yano ◽  
Masahide Mori ◽  
Hidekazu Suzuki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Egfr Mutation ◽  
Acquired Resistance ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Clinical Trial Registration

Aim: Osimertinib is a key drug for EGFR mutation-positive non-small-cell lung cancer (NSCLC). As the hazards ratio of overall survival in comparison with first-generation EGFR-tyrosine kinase inhibitors was almost similar between FLAURA and ARCHER 1050, salvage use of osimertinib is still a treatment option. Patients & methods: We retrospectively analyzed the clinical courses of EGFR mutation-positive NSCLC patients who were potential candidates for salvage osimertinib. Results: Among 524 patients enrolled from five hospitals, 302 patients underwent biopsy, with 52.6% detection rate of T790M. Osimertinib was administered in 93.6% of the T790M-positive patients. The overall response rate and median progression-free survival time of osimertinib were calculated with 147 patients, to be 55.6% and 17.2 months, respectively. Conclusion: Osimertinib is active for T790M-driven acquired resistance in EGFR-mutant NSCLC, but the detection of T790M was unsatisfactory. Clinical Trial Registration: UMIN000028989 (UMIN Clinical Trials Registry)

scholarly journals Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer

JAMA Oncology ◽  
2020 ◽  
Vol 6 (7) ◽  
pp. e201250 ◽  
Author(s):  
Shingo Miyamoto ◽  
Koichi Azuma ◽  
Hidenobu Ishii ◽  
Akihiro Bessho ◽  
Shinobu Hosokawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Low Dose ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Frail Patients

Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation

2014 ◽  
Vol 74 (5) ◽  
pp. 939-946 ◽  
Author(s):  
Satoshi Igawa ◽  
Masashi Kasajima ◽  
Mikiko Ishihara ◽  
Michiko Kimura ◽  
Yasuhiro Hiyoshi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Surface Area ◽  
Body Surface Area ◽  
Cell Lung Cancer ◽  
Body Surface ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document